Clinical Trials Directory

Trials / Conditions / Hormone Receptor Positive HER-2 Negative Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer

12 registered clinical trials studyying Hormone Receptor Positive HER-2 Negative Breast Cancer — 10 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2
NCT07459738
Shanghai Henlius BiotechPhase 2
RecruitingEvaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Meta
NCT06201234
GBG Forschungs GmbHPhase 2
RecruitingA Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurre
NCT06369285
Puma Biotechnology, Inc.Phase 2
RecruitingA Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264
BeiGenePhase 1
RecruitingBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Soli
NCT06120283
BeOne MedicinesPhase 1
RecruitingTCb vs EC-T in High Risk ER+/HER2- Breast Cancer
NCT05901428
Fudan UniversityPhase 3
RecruitingPredicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advan
NCT06805812
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano—
RecruitingImpact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cance
NCT05878314
University Hospital Tuebingen—
RecruitingVS-6766+Abema+Fulv in Met HR+/HER- BC
NCT05608252
Adrienne G. WaksPhase 1 / Phase 2
RecruitingPhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic A
NCT05573126
Ellipses PharmaPhase 1 / Phase 2
CompletedA Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or
NCT06705504
Novartis—
CompletedPalbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
NCT02692755
Georgetown UniversityPhase 2 / Phase 3